What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?

Background With coronavirus disease 2019 (COVID-19) vaccination no longer mandated by many businesses/organizations, it is now up to individuals to decide whether to get any new boosters/updated vaccines going forward. Methods We developed a Markov model representing the potential clinical/economic outcomes from an individual perspective in the United States of getting versus not getting an annual COVID-19 vaccine. Results For an 18–49 year old, getting vaccinated at its current price ($60) can save the individual on average $ 30–$603 if the individual is uninsured and $4–$437 if the individual has private insurance, as long as the starting vaccine efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is ≥50% and the weekly risk of getting infected is ≥0.2%, corresponding to an individual interacting with 9 other people in a day under Winter 2023–2024 Omicron SARS-CoV-2 variant conditions with an average infection prevalence of 10%. For a 50–64 year old, these cost-savings increase to $111–$1278 and $119–$1706 for someone without and with insurance, respectively. The risk threshold increases to ≥0.4% (interacting with 19 people/day), when the individual has 13.4% preexisting protection against infection (eg, vaccinated 9 months earlier). Conclusions There is both clinical and economic incentive for the individual to continue to get vaccinated against COVID-19 each year. [ABSTRACT FROM AUTHOR]